Incyte Corp
(BSP:I1NC34)
R$
221.1
0 (0%)
Market Cap: 85.19 Bil
Enterprise Value: 75.12 Bil
PE Ratio: 541.07
PB Ratio: 4.61
GF Score: 77/100 
Incyte Corp at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 08, 2023 / 06:35PM GMT
Release Date Price:
R$218.46
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Great. It's Michael Schmidt again with the Biotech team from Guggenheim, the next presenting company is Incyte. I'm very excited to welcome Christiana Stamoulis as well as Steven Stein. Welcome, guys, and thanks for joining us.
Steven H. Stein
Incyte Corporation - Executive VP & Chief Medical Officer
Thank you.
Christiana Stamoulis
Incyte Corporation - Executive VP & CFO
Thank you for having us.
Questions & Answers
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
So maybe jumping right into questions sort of in continuation of yesterday's earnings call, Christiana. Starting with Jakafi, which obviously has continued to deliver strong growth last year and guidance look very strong as well. I guess maybe talk a bit about in the commercial setting now, what is the main driver of growth of
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers